Sanara MedTech’s fair value target has shifted from $36 to $34, a $2 adjustment that resets expectations around what investors might be willing to pay for the shares. Analysts link this move to a more ...

White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the ...

The stock of Sanara MedTech (NAS:SMTI, 30-year Financials) gives every indication of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

White Brook Capital provides updates on portfolio holdings including ICON, Perma-Fix, and S&P Global. Read the full analysis ...

FORT WORTH, TX, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we ...

FORT WORTH, TX, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we ...

As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...

FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a provider of surgical ...

4 analysts have expressed a variety of opinions on Sanara MedTech (NASDAQ:SMTI) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates ...

Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve ...